Propanc Biopharma Secures Strategic Financing Agreement with Hexstone Capital for up to $100 Million

Propanc Biopharma has entered into a strategic financing agreement with Hexstone Capital, a family office investing in digital asset treasury companies, for up to $100 million. The deal includes an initial investment of $1 million and the issuance of 9,900 warrants to Hexstone, exercisable for up to $99 million in potential funding. The financing will accelerate the development of Propanc's clinical pipeline and leverage Hexstone's previous investments in DAT companies.